They assessed the diagnostic value of antineuronal antibody levels in the serum and cerebrospinal fluid of 38 SLE patients with and 29 without CNS involvement, in control patients (36 with non-SLE ...

The U.S. Food and Drug Administration has granted regenerative medicine advanced therapy (RMAT) designation to Fate's FT819 ...

when there is evidence for antibody-mediated destruction of red blood cells and/or platelets intravenous immunoglobulin tends to be very efficacious; and when the patient with severe SLE also has ...

The anti-ribosomal P antibody is specific to SLE with a prevalence of 6-36% and is detected predominantly during active disease. [4] Although the mechanism of anti-ribosomal-P-antibody-induced ...

Gómez-Sifontes, A. , Diaz-Tablero, J. and Rodriguez, Y. (2025) Anti-C1q Antibodies as Markers of Renal Involvement in Patients with Systemic Lupus Erythematosus, Bolivar City, Venezuela. Open Access ...

Systemic lupus erythematosus is associated with an increased risk for pulmonary manifestations, including ILD and pulmonary hypertension.

The 321-subject trial is comparing the anti-CD40L antibody to placebo on top of standard care in SLE patients, with the primary endpoint response on the BILAG 2004-based Composite Lupus Assessment ...

The Lupus Research Alliance (LRA) is proud to announce the recipients of this year’s Lupus Innovation Award (LIA), addressing many critical themes in lupus research including novel therapeutic ...

Our cornerstone asset, budoprutug, a potentially best-in-class anti-CD19 monoclonal antibody, is being developed for three initial indications: pMN, ITP, and SLE, each of which represents a ...